Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
about
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyHospitalization rates and discharge status in multiple sclerosisCost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?Estimate of the cost of multiple sclerosis in Spain by literature review.Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.
P2860
Q36171531-91783BAF-9294-41F5-96FB-00EE313A60C0Q36882707-3420E937-5502-4064-8FD4-6F99AEF08ACEQ38197076-54415949-9577-4E3F-8025-4F7DBBF0556CQ38570681-815386D4-9017-4D04-9732-5C08BBE37A9FQ39447194-FDC604A9-99EC-4A89-8E73-CFEBE00DAB4CQ39672574-95D22748-B38E-4078-9DAA-00CAE2C29431Q43647433-8461DC3C-0629-4C40-B3CB-8D940E28BEBFQ47793816-6A79BD70-DB48-4E02-9AC8-56D7FF6061AD
P2860
Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... g multiple sclerosis patients.
@en
Cost-effectiveness analysis of disease modifiying drugs
@nl
type
label
Cost-effectiveness analysis of ...... g multiple sclerosis patients.
@en
Cost-effectiveness analysis of disease modifiying drugs
@nl
prefLabel
Cost-effectiveness analysis of ...... g multiple sclerosis patients.
@en
Cost-effectiveness analysis of disease modifiying drugs
@nl
P2093
P1476
Cost-effectiveness analysis of ...... g multiple sclerosis patients.
@en
P2093
Eliazar Sabater
Miguel Angel Casado
Rafael Arroyo
Rainel Sánchez-de la Rosa
P304
P356
10.3111/13696998.2012.654868
P407
P577
2012-01-27T00:00:00Z